Labcorp Owes Ravgen $273 Million Over Prenatal Test Patents (1)

Diagnostics giant Laboratory Corporation of America Holdings must pay a fetal DNA testmaker $272.5 million for copying a method of screening for Down syndrome and other genetic abnormalities, according to a Texas jury verdict that Ravgen Inc. counsel John M. Desmarais confirmed to Bloomberg Law.

The jury decided after deliberating for about four hours that Labcorp’s method of combining chemicals to stabilize blood samples was too similar to Ravgen’s method of adding formaldehyde to preserve DNA for testing.

“We believe that Ravgen’s claims are wholly without merit and, therefore, we are disappointed with the jury’s verdict and are reviewing our ...